vs

Side-by-side financial comparison of ACV Auctions Inc. (ACVA) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $183.6M, roughly 1.1× ACV Auctions Inc.). On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 15.1%). ACV Auctions Inc. produced more free cash flow last quarter ($-14.7M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 12.3%).

ACV Auctions Inc. operates a leading digital wholesale vehicle auction platform serving automotive dealers across the U.S. and Canada. It offers end-to-end services including transparent vehicle inspections, secure payment processing, and logistics support, enabling efficient trading of used vehicles between registered wholesale buyers and sellers.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

ACVA vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.1× larger
RARE
$207.3M
$183.6M
ACVA
Growing faster (revenue YoY)
RARE
RARE
+10.8% gap
RARE
25.9%
15.1%
ACVA
More free cash flow
ACVA
ACVA
$86.1M more FCF
ACVA
$-14.7M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
12.3%
ACVA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACVA
ACVA
RARE
RARE
Revenue
$183.6M
$207.3M
Net Profit
$-128.6M
Gross Margin
Operating Margin
-9.7%
-54.7%
Net Margin
-62.0%
Revenue YoY
15.1%
25.9%
Net Profit YoY
3.5%
EPS (diluted)
$-0.12
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACVA
ACVA
RARE
RARE
Q4 25
$183.6M
$207.3M
Q3 25
$199.6M
$159.9M
Q2 25
$193.7M
$166.5M
Q1 25
$182.7M
$139.3M
Q4 24
$159.5M
$164.6M
Q3 24
$171.3M
$139.5M
Q2 24
$160.6M
$147.0M
Q1 24
$145.7M
$108.8M
Net Profit
ACVA
ACVA
RARE
RARE
Q4 25
$-128.6M
Q3 25
$-24.5M
$-180.4M
Q2 25
$-7.3M
$-115.0M
Q1 25
$-14.8M
$-151.1M
Q4 24
$-133.2M
Q3 24
$-16.0M
$-133.5M
Q2 24
$-17.1M
$-131.6M
Q1 24
$-20.5M
$-170.7M
Operating Margin
ACVA
ACVA
RARE
RARE
Q4 25
-9.7%
-54.7%
Q3 25
-11.9%
-106.9%
Q2 25
-3.7%
-64.8%
Q1 25
-7.9%
-102.6%
Q4 24
-16.2%
-74.3%
Q3 24
-10.0%
-94.6%
Q2 24
-11.6%
-79.1%
Q1 24
-15.5%
-151.9%
Net Margin
ACVA
ACVA
RARE
RARE
Q4 25
-62.0%
Q3 25
-12.3%
-112.8%
Q2 25
-3.8%
-69.0%
Q1 25
-8.1%
-108.5%
Q4 24
-80.9%
Q3 24
-9.4%
-95.7%
Q2 24
-10.6%
-89.5%
Q1 24
-14.1%
-156.8%
EPS (diluted)
ACVA
ACVA
RARE
RARE
Q4 25
$-0.12
$-1.28
Q3 25
$-0.14
$-1.81
Q2 25
$-0.04
$-1.17
Q1 25
$-0.09
$-1.57
Q4 24
$-0.15
$-1.34
Q3 24
$-0.10
$-1.40
Q2 24
$-0.10
$-1.52
Q1 24
$-0.13
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACVA
ACVA
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$271.5M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$429.7M
$-80.0M
Total Assets
$1.1B
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACVA
ACVA
RARE
RARE
Q4 25
$271.5M
$421.0M
Q3 25
$265.3M
$202.5M
Q2 25
$258.4M
$176.3M
Q1 25
$291.9M
$127.1M
Q4 24
$224.1M
$174.0M
Q3 24
$252.5M
$150.6M
Q2 24
$215.0M
$480.7M
Q1 24
$209.8M
$112.3M
Stockholders' Equity
ACVA
ACVA
RARE
RARE
Q4 25
$429.7M
$-80.0M
Q3 25
$434.4M
$9.2M
Q2 25
$448.8M
$151.3M
Q1 25
$439.6M
$144.2M
Q4 24
$440.0M
$255.0M
Q3 24
$456.2M
$346.8M
Q2 24
$457.6M
$432.4M
Q1 24
$458.3M
$140.3M
Total Assets
ACVA
ACVA
RARE
RARE
Q4 25
$1.1B
$1.5B
Q3 25
$1.2B
$1.2B
Q2 25
$1.1B
$1.3B
Q1 25
$1.2B
$1.3B
Q4 24
$984.1M
$1.5B
Q3 24
$1.0B
$1.5B
Q2 24
$1.0B
$1.6B
Q1 24
$1.0B
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACVA
ACVA
RARE
RARE
Operating Cash FlowLast quarter
$-12.4M
$-99.8M
Free Cash FlowOCF − Capex
$-14.7M
$-100.8M
FCF MarginFCF / Revenue
-8.0%
-48.6%
Capex IntensityCapex / Revenue
1.2%
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$69.1M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACVA
ACVA
RARE
RARE
Q4 25
$-12.4M
$-99.8M
Q3 25
$10.3M
$-91.4M
Q2 25
$13.7M
$-108.3M
Q1 25
$66.6M
$-166.5M
Q4 24
$-3.2M
$-79.3M
Q3 24
$21.1M
$-67.0M
Q2 24
$4.5M
$-77.0M
Q1 24
$43.0M
$-190.7M
Free Cash Flow
ACVA
ACVA
RARE
RARE
Q4 25
$-14.7M
$-100.8M
Q3 25
$7.7M
$-92.7M
Q2 25
$10.9M
$-110.7M
Q1 25
$65.3M
$-167.8M
Q4 24
$-3.9M
$-79.5M
Q3 24
$20.2M
$-68.6M
Q2 24
$2.7M
$-79.0M
Q1 24
$41.9M
$-193.9M
FCF Margin
ACVA
ACVA
RARE
RARE
Q4 25
-8.0%
-48.6%
Q3 25
3.8%
-58.0%
Q2 25
5.6%
-66.5%
Q1 25
35.7%
-120.5%
Q4 24
-2.5%
-48.3%
Q3 24
11.8%
-49.2%
Q2 24
1.7%
-53.7%
Q1 24
28.8%
-178.2%
Capex Intensity
ACVA
ACVA
RARE
RARE
Q4 25
1.2%
0.5%
Q3 25
1.3%
0.8%
Q2 25
1.5%
1.5%
Q1 25
0.7%
1.0%
Q4 24
0.4%
0.1%
Q3 24
0.6%
1.2%
Q2 24
1.1%
1.4%
Q1 24
0.7%
3.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACVA
ACVA

Auction Marketplace Revenue$77.6M42%
Other Marketplace Revenue$72.4M39%
Customer Assurance$24.1M13%
Data Services Revenue$9.4M5%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons